The world's biggest CRO Quintiles and a number of international investors have come together to create a new fund aimed at lightening the cost burden of pharma drug development.
Janssen has signed up two more therapy areas to its unique Disease Interception Accelerator (DIA) program as it continues to look for future growth and deals from new places.
The U.K.'s National Health Service doesn't have the reputation of being particularly technology savvy. In fact, it's had a long and public struggle--that's not yet complete--to get electronic medical records into place.
Big Pharma and Boehringer Ingelheim are expanding their "smart inhaler" partnership with Madison, WI's Propeller Health. Respimat patients will have the opportunity to enroll in a program offered at select U.S. medical centers that's designed to determine how smart inhaler tolls affect adherence rates and patient engagement, the companies said in a release.
Hangzhou-based Zhejiang Medicine, or ZMC, has started Phase I work in Australia and New Zealand on an antibody candidate targeting HER2-positive breast cancer with San Diego-based Ambrx, building on a 2013 partnership.
French CRO NovAliX has penned a new partnership with microscopy specialist FEI as it looks to broaden its offering to biopharma clients.
Beijing-based CANbridge Life Sciences has built on its aim to expand licensing opportunities with a potential $134 million deal with Nasdaq-listed Aveo Oncology for a clinical-stage ErbB3 (HER3) antibody candidate AV203.
Late last year, GE Healthcare announced that it would be taking its imaging data and analysis to the cloud. It's now revealed one of the first software applications that will be available via the GE Health Cloud: an automated, biomarker-based quantitative lung imaging analysis from Minneapolis startup Imbio.
Biopharmas are interested in incorporating wearables that offer continuous patient monitoring into clinical trials of their drug candidates. But it's still early in terms of understanding of how these sorts of data can be used--and what regulators will make of them.
Eli Lilly CEO John Lechleiter has done the rounds in Asia with a recent stop in China an occasion for a chat about the company's plans in the Middle Kingdom with China Daily.